Vaccines
|
247
Table 7. Incident SARS-CoV-2 infection among 3990 unvaccinated nursing home residents Total
Asymptomatic SARS-CoV-2 infection
Symptomatic SARS-CoV-2 infection
Percent of infected residents who were asymptomatic
173 (4.3%)
115 (2.9%)
58 (1.5%)
66.5
Positive test at 0-14 days* at 15-28 days*
69 (1.7%)
42 (1.1%)
27 (0.7%)
60.9
at 29-42 days*
16 (0.4%)
13 (0.3%)
3 (0.1%)
81.2
at > 42 days
12 (0.3%)
10 (0.3%)
2 (0.1%)
83.3
* After first vaccination at the nursing home
Single Vaccines The BioNTech/Pfizer vaccine History and approval In November 2020, the German company BioNTech and the New York-based Pfizer made history by presenting data which indicated that their vaccine tozinameran (formerly BNT162b2; trade name: Comirnaty™) had an extraordinary efficacy of over 90%. Four months later, these results were reproduced in a spectacular real-life analysis of almost 1.2 million people in Israel. The estimated effectiveness of the BioNTech/Pfizer vaccine after the second dose was 92% for documented infection, 94% for symptomatic COVID-19, 87% for hospitalization, and 92% for severe COVID-19 (Table 8) (Dagan 2021). The vaccine has gained full approval or authorization for emergency use (people 16 years of age) in more than 100 countries. In May, Canada and the US authorized the vaccine for children aged 12 to 15 (Health Canada 20210505, Wallace 2021).
COVID Reference ENG 006.9
